Neurotrophic factor synthesis and TrkB/A receptor activation
BDNF / NGF & Trk Signaling · Neurotransmission and synaptic plasticity
Stimulates astrocytes and neurons to transcribe and release brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), activating TrkB/A receptors to promote new synapse formation and neuron survival.
Supplements acting on this mechanism (ranked by strength and evidence)
Bacopa monnieri extract (bacosides)
One randomized trial in 80 people found higher serum BDNF than in the placebo group after 300 mg/day for 12 weeks. An open-label study in older adults, however, found no change in serum BDNF after 12 weeks. Changes in hippocampal TrkB receptors and dendritic spines have been seen mainly in animals.
Magnesium L-threonate
In some rat models, magnesium L-threonate raised BDNF expression and synaptic marker levels. Whether the same changes occur in humans remains to be tested. There is no reliable evidence that usual doses produce equivalent changes in the human brain.
Lion’s mane extract
Lion’s mane compounds can modulate NGF and BDNF expression in some animal and cell models. Claims that they efficiently cross the human blood-brain barrier or clearly activate TrkA have not been confirmed. The neurotrophic factor changes come mainly from animal and cell data, and their role in humans is unclear.
Polygala tenuifolia extract
In chronically stressed rats, Polygala extract can affect hippocampal BDNF and TrkB mRNA expression, but the evidence is mainly limited to animals. There is no reliable trial evidence in humans for rapid TrkB activation or synaptic long-term potentiation, and an antidepressant effect cannot be inferred from these findings.
Scallop plasmalogens
In mice, dietary plasmalogens can increase BDNF signaling in the hippocampus, and the related effects weakened when BDNF or TrkB was knocked down. In a 12-week human randomized trial, plasma BDNF did not differ significantly between groups, so the evidence for this neurotrophic pathway in humans is still limited.
Natural full-spectrum tocotrienols
In a randomized trial in patients with diabetic peripheral neuropathy, serum NGF rose after taking a tocotrienol-rich formulation (400 mg daily). This result does not establish that BDNF or Trk receptors were activated in the brain, and it cannot be extended to lower doses.
Alpha-GPC (alpha-glycerylphosphorylcholine)
In high-dose animal experiments, oral alpha-GPC was associated with increased hippocampal BDNF expression. The causal pathway between cholinergic stimulation and BDNF upregulation has not been confirmed, and its role in humans is also unclear.
Citicoline
In rats with nerve injury, a higher dose of citicoline given by intraperitoneal injection raised BDNF gene expression in the trigeminal ganglion on day 3. This is an animal result at a high dose, so it cannot be assumed that usual oral dosing has the same effect in the human brain. Changes in synaptophysin also do not represent the BDNF or NGF pathway.
Methylcobalamin (active methyl B12)
In injured mice given intraperitoneal methylcobalamin, BDNF and NGF expression rose in dorsal root ganglia. Data on Schwann cells and myelin regeneration come mostly from cell and rat studies. This mechanism has not been confirmed in humans, and the effect of usual oral doses is also unclear.
Uridine monophosphate (UMP)
Nucleotides such as UTP can activate P2Y2 receptors, and in cell studies this receptor interacts with NGF/TrkA signaling. But these cell results cannot be extrapolated directly to UMP. There is currently no direct evidence on how UMP relates to the TrkB pathway, or on whether oral UMP changes BDNF and NGF signaling in humans.
Pyrroloquinoline quinone (PQQ)
In cultured astrocytes, PQQ can promote the synthesis or secretion of NGF. The study that found increased NGF in the rat brain used a PQQ derivative, so it cannot be applied directly to oral PQQ. There is no evidence yet of the same change in the human brain.